Drug Combo Improves Symptoms of Menopause in Animal Study

Bazedoxifene with estrogens affect hot flashes, bone mass and cholesterol in rats

FRIDAY, Aug. 22 (HealthDay News) -- A combination of bazedoxifene and conjugated estrogens can improve menopausal symptoms such as hot flashes, reduced bone mass and increased cholesterol in a rat model, according to the results of a study published online Aug. 14 in Endocrinology.

Yogendra Kharode and colleagues from Wyeth Research in Collegeville, Pa., tested bazedoxifene with conjugated estrogens as a tissue selective estrogen complex (the combination of a selective estrogen receptor modulator plus estrogens) on uterine, vasomotor, lipid and skeletal responses in mature ovariectomized rats (as a model of osteopenia).

The researchers found that 3 mg/kg bazedoxifene blocked uterine stimulation by conjugated estrogens, but maintained the positive effect of the estrogens on vasomotor instability (based on the rat tail skin temperature model). The combination also reduced total cholesterol levels by up to 20 percent compared with estrogens alone and significantly increased total bone density compared with no treatment.

"These preclinical findings showed that the appropriate dose combination of bazedoxifene/conjugated estrogens exhibits positive vasomotor, lipid and skeletal responses with minimal uterine stimulation," Kharode and colleagues conclude.

The study was supported by Wyeth Research, and all of the authors are or were previously employed by Wyeth.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing